Resources
Health Care Professional Resources
.
LUTATHERA Clinical Overview Brochure
This brochure provides an overview of the NETTER-1 and NETTER-2 clinical trials, which support the use of LUTATHERA in patients who are newly diagnosed or who have progressed after SSA therapy.
LUTATHERA Patient Identification Guide
This brochure discusses the importance of early progression detection and prompt LUTATHERA treatment for patients who have progressed on an SSA, like those included in the NETTER-1 clinical trial.
LUTATHERA Radiation Safety Brochure
This guide offers key information about radiation exposure and guidelines for radiation safety for those involved in caring for patients being treated with LUTATHERA, such as administering nurses and patients’ loved ones.
LUTATHERA NCCN Guideline Update Flashcard
This digital piece outlines select recommendations from the latest NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for lutetium Lu 177 dotatate (LUTATHERA®).
Nurse-specific resources
LUTATHERA Administering Brochure
This guide is intended for nurses assisting in LUTATHERA administration at treatment centers. It enables them to ask their patients the right questions, coordinate the steps involved in treatment readiness, and anticipate patient considerations.
LUTATHERA Referral Brochure
This is a helpful guide intended for nurses in the oncologist’s practice. It helps them learn to identify appropriate patients for LUTATHERA, answer patient questions about the treatment process, and prepare to coordinate their treatment.
Learn what a medical expert has to say about LUTATHERA
GEP-NETs and LUTATHERA
Join Sandy Kotiah, MD, as she walks through the need for earlier intervention in GEP-NETs, an introduction to LUTATHERA, and the LUTATHERA mechanism of action.
LUTATHERA in NETTER-1 and NETTER-2
Sandy Kotiah, MD, provides a brief review of the efficacy and safety of LUTATHERA in the NETTER-1 and NETTER-2 trials.
Identifying Patients for LUTATHERA Therapy
Sandy Kotiah, MD, shares her perspectives on which patients may be eligible for LUTATHERA therapy, insights on identifying progression in GEP-NETs, and resources for providers and patients.
GEP-NETs, gastroenteropancreatic neuroendocrine tumors; NCCN, National Comprehensive Cancer Network; SSA, somatostatin analogue.